Company Overview
Tenon Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it develops and markets implant solutions designed to treat severe lower back pain in the United States. The company's primary product offering is the Catamaran SI-Joint Fusion System, which utilizes a titanium implant for an invasive approach to the sacroiliac joint to address spinal conditions. As of the latest reported data, the company holds a market capitalization of $7.77M and generated total revenue of $3.94M over the trailing twelve months, while the employee count is not publicly disclosed in the available records. These financial figures indicate that Tenon Medical is a small-cap entity with a relatively modest revenue base compared to established large-cap medical device peers, suggesting a niche market position with significant growth potential but limited scale in terms of market share and operational footprint.
Financial Health
The company reported a trailing twelve-month revenue of $3.94M alongside a net income of -$12,556,000 and an EBITDA of -$12,569,333, revealing a substantial divergence between top-line sales and bottom-line profitability. This significant gap between revenue and net income highlights a cost structure where operating expenses, likely including research and development costs for the Catamaran system, far exceed the gross profit generated by current sales. Regarding cash flow dynamics, the company has reported free cash flow as N/A in the provided data, which suggests that cash flow metrics are not yet stabilized or disclosed, potentially indicating limited financial flexibility to fund operations without external capital. The margin profile presents a mixed picture with a gross margin of 59.8%, an operating margin of -246.1%, and a profit margin of 0.0%, indicating that while the core product is priced favorably, high overhead costs are erding operating income to the point where the company is not generating net profit. In terms of solvency, the company holds $3.76M in cash against $141,000 in debt, resulting in a debt-to-equity ratio of 2.80, which characterizes the balance sheet as leveraged given the high debt relative to equity despite the low absolute dollar amount of debt. Liquidity is assessed via a current ratio of 2.11, which indicates that the company possesses more than double the current assets needed to cover its short-term liabilities, providing a buffer for operational continuity. However, return metrics such as a return on equity of -228.1% and a return on assets of -77.6% reveal that management has not yet achieved positive capital efficiency, as the company is generating losses on both shareholders' equity and its total asset base.
Valuation Assessment
Valuation metrics for Tenon Medical reflect its status as a pre-profitability entity with a trailing P/E ratio of N/A and a forward P/E of -1.12, implying that earnings are currently negative and future earnings estimates are projected to remain negative or require significant improvement before traditional multiple analysis applies. The price-to-book ratio stands at 3.87, indicating that the market values the company at nearly four times its net asset book value, which suggests investors are pricing in significant future growth expectations or intangible value beyond the tangible assets listed on the balance sheet. Alternative valuation measures such as a price-to-sales ratio of 1.97 and an EV/EBITDA of -0.56 further underscore the reliance on sales-based metrics rather than earnings-based ones, as the negative EV/EBITDA confirms the company is burning cash relative to its enterprise value. The stock has exhibited considerable price volatility, trading between a 52-week high of $5.85 and a 52-week low of $0.64, meaning the current market price sits within a wide range that reflects high uncertainty regarding the company's near-term performance trajectory. The beta value of 1.25 indicates that the stock is 25% more volatile than the broader market, suggesting that price movements for TNON will likely amplify market swings, particularly during periods of increased volatility in the healthcare sector.
Growth & Income
Tenon Medical has demonstrated aggressive top-line expansion with a revenue growth rate of 92.3% year-over-year, whereas earnings growth is listed as N/A due to the company's persistent net losses, implying that sales expansion is outpacing profitability improvements as the firm scales its implant distribution. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders, although current losses limit the actual amount available for reinvestment. Since the company is not a dividend payer, the income profile is non-existent for income-focused investors, and the primary investment thesis relies entirely on the potential for future earnings turnaround driven by the adoption of the SI-Joint Fusion System. Overall, the growth and income profile is characterized by high revenue acceleration coupled with deep operational losses and a lack of current cash distributions, presenting a high-risk, high-potential-reward scenario typical of early-stage medical device development firms.